Skip to main content
. 2020 Mar 31;9(4):963. doi: 10.3390/jcm9040963
aPTT activated partial thromboplastin time
CI confidence intervals
CRP C-reactive protein
CT computed tomography
DVT deep vein thrombosis
ECMO extracorporeal membrane oxygenation
HR heparin resistance
ITT intention-to-treat
MODS multiple organ dysfunction syndrome
OR odds ratio
SAE serious adverse events
SAR serious adverse reactions
SCI spinal cord injuries
UFH unfractionated heparin
V visit (study visits at pre-defined time points)
VTE venous thromboembolism